Correction of X-Linked Lymphoproliferative Disease by Transplantation of Cord-Blood Stem Cells

Abstract

X-linked lymphoproliferative disease is characterized by vulnerability to diseases induced by the Epstein-Barr virus, including life-threatening infectious mononucleosis, hypogammaglobulinemia, aplastic anemia, and B-cell non-Hodgkin's lymphoma. It is uniformly fatal by the age of 40 years1. Bone marrow transplantation has the potential to correct this defect and has been performed with HLA-matched family members or unrelated persons as donors. One patient had a return of serum IgG1 and IgG3 concentrations to normal but died of an adenovirus infection 84 days after bone marrow transplantation2. Two other patients died 23 and 60 days after bone marrow transplantation as a result . . .